UB Paderborn / Katalog / Suche / in CDI

Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Journal of the American College of Cardiology, 2014-04, Vol.63 (16), p.1644-1653

2014

Volltextzugriff (PDF)

Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I

Journal of the American College of Cardiology, 2010-05, Vol.55 (19), p.2118-2124

2010

Volltextzugriff (PDF)

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c

The American journal of medicine, 2016-03, Vol.129 (3), p.340.e1-340.e8

2016

Volltextzugriff (PDF)

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

The American heart journal, 2009-09, Vol.158 (3), p.335-341.e3

2009

Volltextzugriff (PDF)

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study

The American heart journal, 2011-11, Vol.162 (5), p.818-825.e6

2011

Volltextzugriff (PDF)

Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

Journal of the American College of Cardiology, 2012-10, Vol.60 (17), p.1623-1630

2012

Volltextzugriff (PDF)

Cardiac arrest and therapeutic hypothermia

Trends in cardiovascular medicine, 2016-05, Vol.26 (4), p.337-344

2016

Volltextzugriff (PDF)

COCATS 4 Task Force 13: Training in Critical Care Cardiology

Journal of the American College of Cardiology, 2015-05, Vol.65 (17), p.1877-1886

2015

Volltextzugriff (PDF)

Editorial commentary: Treating patients with diabetes and cardiovascular disease—Does the glucose matter?

Trends in cardiovascular medicine, 2016-02, Vol.26 (2), p.180-181

Scirica, Benjamin M., MD, MPH

2016

Volltextzugriff (PDF)

Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50)

The American journal of cardiology, 2016-04, Vol.117 (7), p.1055-1058

2016

Volltextzugriff (PDF)

Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction

JACC. Cardiovascular interventions, 2010-11, Vol.3 (11), p.1166-1177

2010

Volltextzugriff (PDF)

Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TIMI 36 Trial of Ranolazine Versus Placebo

The American journal of cardiology, 2014-07, Vol.114 (1), p.17-23

2014

Volltextzugriff (PDF)

Long-Term Management and Unmet Needs After an Acute Coronary Syndrome Event

The American journal of cardiology, 2015, Vol.115 (5), p.29A-35A

2015

Volltextzugriff (PDF)

Coronary Stent Thrombosis With Vorapaxar Versus Placebo

Journal of the American College of Cardiology, 2014-12, Vol.64 (22), p.2309-2317

2014

Volltextzugriff (PDF)

New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo

Journal of the American College of Cardiology, 2014-12, Vol.64 (22), p.2318-2326

2014

Volltextzugriff (PDF)

Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock

Journal of the American College of Cardiology, 2016-02, Vol.67 (7), p.739-747

2016

Volltextzugriff (PDF)

High-Sensitivity Troponin in the Triage of Acute Decompensated Heart Failure

JACC. Heart failure, 2016-07, Vol.4 (7), p.600-602

2016

Volltextzugriff (PDF)

Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non–ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial)

The American journal of cardiology, 2011-11, Vol.108 (10), p.1373-1381

2011

Volltextzugriff (PDF)

Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: Analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY) - Thrombolysis in Myocardial Infarction (TIMI) 28

The American heart journal, 2010-06, Vol.159 (6), p.964-971.e1

2010

Volltextzugriff (PDF)

Relation of Death Within 90 Days of Non-ST-Elevation Acute Coronary Syndromes to Variability in Electrocardiographic Morphology

The American journal of cardiology, 2009-02, Vol.103 (3), p.307-311

2009

Volltextzugriff (PDF)

Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction

The American heart journal, 2010, Vol.159 (1), p.55-62

2010

Volltextzugriff (PDF)

Reply

Journal of the American College of Cardiology, 2010, Vol.56 (10), p.822-823

2010

Volltextzugriff (PDF)

The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Journal of the American College of Cardiology, 2011-05, Vol.57 (19), p.1908-1916

2011

Volltextzugriff (PDF)

B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

Journal of the American College of Cardiology, 2010-03, Vol.55 (12), p.1189-1196

2010

Volltextzugriff (PDF)

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

Journal of the American College of Cardiology, 2011-02, Vol.57 (6), p.672-684

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study

Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

Cardiac arrest and therapeutic hypothermia

COCATS 4 Task Force 13: Training in Critical Care Cardiology

Editorial commentary: Treating patients with diabetes and cardiovascular disease—Does the glucose matter?

Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50)

Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction

Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TIMI 36 Trial of Ranolazine Versus Placebo

Long-Term Management and Unmet Needs After an Acute Coronary Syndrome Event

Coronary Stent Thrombosis With Vorapaxar Versus Placebo

New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo

Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock

High-Sensitivity Troponin in the Triage of Acute Decompensated Heart Failure

Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non–ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial)

Relation of Death Within 90 Days of Non-ST-Elevation Acute Coronary Syndromes to Variability in Electrocardiographic Morphology

Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction

Reply

The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

Suchergebnisse filtern